Page last updated: 2024-12-08

allylestrenol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Allylestrenol: A synthetic steroid with progestational activity. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID235905
CHEMBL ID3185133
CHEBI ID31189
SCHEMBL ID329623
MeSH IDM0000752

Synonyms (98)

Synonym
17.alpha.-allyl-4-oestrene-17.beta.-ol
17.alpha.-allylestr-4-en-17.beta.-ol
nsc37723
organon
17.alpha.-allyl-17-.beta.-hydroxy-.delta.(sup 4)-estren
gestanyn
gestanin
estr-4-en-17.beta.-ol, 17-allyl-
estrenol, allyl-
17.alpha.-allyl-4-estren-17.beta.-ol
17.alpha.-allylestrenol
17.alpha.-allyl-3-deoxy-19-nortestosterone
gestanon-r
gestanon
17.alpha.-allyl-17.beta.-hydroxy-4-estrene
wln: l e5 b666 mutj e1 fq f2u1
orageston
17.alpha.-allyl-4-destrene-17.beta.-ol
turinal
estr-4-en-17-ol, (17.beta.)-
nsc-37723
gestanol
(17beta)-17-prop-2-en-1-ylestr-4-en-17-ol
19-norpregn-4-ene-20-yn-17beta-ol
LMST02030125
nsc 37723
estr-4-en-17-ol, 17-(2-propenyl)-, (17beta)-
17-alpha-allylestr-4-en-17-beta-ol
17alpha-allyl-3-deoxy-19-nortestosterone
17-alpha-allyl-17-beta-hydroxy-delta(sup 4)-estren
estr-4-en-17-beta-ol, 17-allyl-
3-deoxy-17-alpha-allyl-19-nortestosterone
17-alpha-allyl-4-oestrene-17-beta-ol
allylestrenolum [inn-latin]
brn 3148038
17alpha-allyl-4-destrene-17beta-ol
alilestrenol [inn-spanish]
17-alpha-allylhydroxy-19-nor-4-androstene
21-methylene-19-nor-17-alpha-preg-4-en-17-ol
17alpha-allyl-19-nor-delta-4-androstene-17beta-ol
estr-4-en-17beta-ol, 17-allyl-
17alpha-allyl-4-oestrene-17beta-ol
17-alpha-allyl-3-deoxy-19-nortestosterone
17alpha-allylestrenol
17alpha-allyl-17beta-hydroxy-4-estrene
allyloestrenolum
17-alpha-allyl-17-beta-hydroxy-4-estrene
17alpha-allyl-4-estren-17beta-ol
einecs 207-082-9
19-nor-17-alpha-preg-4-en-17-ol, 21-methylene-
17-hydroxy-17-alpha-allyl-4-estrene
ccris 9068
allilestrenolo [dcit]
allylestrenol
432-60-0
17alpha-allylestr-4-en-17beta-ol
NCGC00159497-02
allyloestrenol
DB01431
allyl estrenol
3-deketo-17alpha-allyl-19-nortestosterone
D01374
perselin (tn)
allylestrenol (jan/inn)
(8r,9s,10r,13s,14s,17r)-13-methyl-17-prop-2-enyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ol
i47vb5dz8o ,
unii-i47vb5dz8o
alilestrenol
allylestrenolum
allylestrenol [inn:ban:jan]
allilestrenolo
4-06-00-04143 (beilstein handbook reference)
tox21_111718
dtxcid902574
cas-432-60-0
dtxsid9022574 ,
perselin
AKOS015964938
A2570
S5219
allylestrenol [jan]
allylestrenol [mi]
allylestrenol [mart.]
allylestrenol [who-dd]
allylestrenol [inn]
SCHEMBL329623
CHEBI:31189 ,
CHEMBL3185133
17-allylestr-4-en-17-beta-ol
SR-01000883956-1
sr-01000883956
CS-0006769
HY-17375
estr-4-en-17-ol, 17-(2-propenyl)-, (17b)-
DS-8255
Q531965
mfcd00198957
BCP10809

Research Excerpts

Overview

Allylestrenol is an oral progestogen being increasingly used for luteal phase support in assisted reproductive techniques. It is an effective and safe medical treatment for patients with symptomatic BPH.

ExcerptReferenceRelevance
"Allylestrenol is an oral progestogen being increasingly used for luteal phase support in assisted reproductive techniques. "( Evaluation of allylestrenol for clinical pregnancies in patients treated with assisted reproductive techniques: a retrospective, propensity score matched, observational study.
Ding, W; Sun, K; Xiu, Y; Xu, X; Yu, T; Yu, Y; Zhang, Q; Zhao, M, 2023
)
2.71
"Allylestrenol is an effective and safe medical treatment for patients with symptomatic BPH. "( Clinical significance of interruption of therapy with allylestrenol in patients with benign prostatic hypertrophy.
Fukuoka, H; Fukushima, S; Harada, M; Hosaka, M; Kinoshita, Y; Masuda, M; Miyai, K; Noguchi, K; Takeda, M, 1998
)
1.99
"Allylestrenol in particular is an interesting gestagen due to its inherent oestrogenic effect in the absence of an androgenic effect."( [Lynestrenol and allylestrenol in the therapy of postmenopausal hot flushes].
Barták, A; Blovský, J; Rozprávka, M, 1992
)
1.34

Compound-Compound Interactions

ExcerptReferenceRelevance
" Effectiveness of 5-fluorouracil in combination with hormones (estrogen or gestagen) in low doses, as a basal treatment, was compared with that of hormones alone in high doses."( [Effectiveness of 5-fluorouracil combined with hormones in low dose as a basal treatment for prostatic carcinoma].
Takeuchi, H, 1984
)
0.27

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Each agent was orally administered to 58 patients in a dosage of 50 mg/day for 12 consecutive weeks."( [Effects of anti-androgens on sexual function. Double-blind comparative studies on allylestrenol and chlormadinone acetate Part I: Nocturnal penile tumescence monitoring].
Kadono, M; Kato, S; Kumamoto, Y; Maki, A; Matsumoto, H; Mori, K; Sato, Y; Suzuki, R; Tanda, H; Yamaguchi, Y, 1990
)
0.5
" Each test drug was orally administered to 58 patients, in a daily dosage of 50 mg for 12 consecutive weeks."( [Effects of anti-androgens on sexual function. Double-blind comparative studies on allylestrenol and chlormadinone acetate. Part II: Self-assessment questionnaire method].
Kadono, M; Kato, S; Kumamoto, Y; Maki, A; Matsumoto, H; Mori, K; Sato, Y; Suzuki, R; Tanda, H; Yamaguchi, Y, 1990
)
0.5
"A trial to reduce the dosage of estrogen or to substitute it by other agents was done as a treatment of prostatic carcinoma."( The therapeutic effect of concurrent administration of 5-fluorouracil and allylestrenol or hexestrol in small doses on prostatic carcinoma.
Takeuchi, H, 1981
)
0.49
" Allyloestrenol (Gestanon) was given at a dosage of 10 mg daily until the 8th week of pregnancy; the dosage was then stepped up to 15 to 20 mg daily until the 12th week of pregnancy and then rapidly tailed off."( [The incidence of congenital abnormalities following gestagen administration in early pregnancy (author's transl)].
Philipp, K; Schmid, R; Schneider, WH, 1981
)
0.26
" dosing with 100 mg kg-1 once a week for 6 successive weeks, the values of the number and area of gamma-glutamyltranspeptidase-positive foci were, as compared to controls, 15."( Induction of micronuclei and of enzyme-altered foci in the liver of female rats exposed to progesterone and three synthetic progestins.
Allavena, A; Brambilla, G; De Pascalis, CR; Ghia, M; Martelli, A; Mereto, E; Orsi, P, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
steroidAny of naturally occurring compounds and synthetic analogues, based on the cyclopenta[a]phenanthrene carbon skeleton, partially or completely hydrogenated; there are usually methyl groups at C-10 and C-13, and often an alkyl group at C-17. By extension, one or more bond scissions, ring expansions and/or ring contractions of the skeleton may have occurred. Natural steroids are derived biogenetically from squalene which is a triterpene.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.00710.003245.467312,589.2998AID2517
AR proteinHomo sapiens (human)Potency11.60500.000221.22318,912.5098AID743035; AID743040; AID743042; AID743063
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency17.19750.000214.376460.0339AID720691; AID720692
pregnane X nuclear receptorHomo sapiens (human)Potency28.18380.005428.02631,258.9301AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency8.51910.000229.305416,493.5996AID743069; AID743075; AID743077; AID743079; AID743080
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency33.49150.000323.4451159.6830AID743065; AID743067
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1150122Relative binding affinity to sheep progesterone receptor1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Quantitative relationships between steroid structure and binding to putative progesterone receptors.
AID1150124Relative binding affinity to guinea pig progesterone receptor1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Quantitative relationships between steroid structure and binding to putative progesterone receptors.
AID1150121Relative binding affinity to human progesterone receptor1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Quantitative relationships between steroid structure and binding to putative progesterone receptors.
AID1150123Relative binding affinity to rabbit progesterone receptor1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Quantitative relationships between steroid structure and binding to putative progesterone receptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (129)

TimeframeStudies, This Drug (%)All Drugs %
pre-199082 (63.57)18.7374
1990's36 (27.91)18.2507
2000's7 (5.43)29.6817
2010's2 (1.55)24.3611
2020's2 (1.55)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 51.97

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index51.97 (24.57)
Research Supply Index5.02 (2.92)
Research Growth Index4.25 (4.65)
Search Engine Demand Index82.90 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (51.97)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials15 (11.11%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (0.74%)4.05%
Observational1 (0.74%)0.25%
Other118 (87.41%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]